Druggable CSNK2A1-MeCP2 regulatory axis links Okur-Chung neurodevelopmental syndrome with MECP2-related disorders

A CSNK2A1-driven regulatory axis stabilizes MeCP2, and inhibiting CSNK2A1 reduces MeCP2 dysregulation linked to MECP2 duplication syndrome and Okur-Chung neurodevelopmental syndrome.

• Why it matters: MeCP2 abundance must stay tightly controlled, but the proteins that regulate functional MeCP2—and whether they are druggable—remain unclear.
• What they did: Genome-wide CRISPR knockout screens in human cells identified hundreds of MeCP2 regulators, highlighting CSNK2A1; a novel CSNK2A1 inhibitor was tested in human cells and Csnk2a1 was targeted in an MDS mouse model.
• The result: In an OCNDS mouse model, CSNK2A1 disruption is linked to ~50% less hippocampal MeCP2, supporting a druggable CSNK2A1–MeCP2 axis for therapeutic relevance.

AI summary of the abstract · may contain errors · not medical advice · read the paper.